Form 4: Assertio Holdings Acquired by Zydus in $23.50 Cash Deal

Director Heather L. Mason reports the disposal of all equity holdings in Assertio Holdings, Inc. following the company's acquisition by Zydus Worldwide DMCC.

Summary

• Assertio Holdings, Inc. has been acquired by Zydus Worldwide DMCC via a tender offer and subsequent merger.
• The transaction was completed on June 16, 2026, at an offer price of $23.50 per share in cash.
• Reporting person Heather L. Mason disposed of all direct and indirect common stock holdings as part of the merger.
• All outstanding stock options and restricted stock units were cancelled and converted into the right to receive cash payments based on the $23.50 offer price.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents the final administrative step of a completed acquisition rather than a change in operational performance.

Positives

• Shareholders received a cash exit at $23.50 per share.
• Unvested restricted stock units were accelerated and fully vested prior to the merger completion.
• In-the-money stock options were converted into cash payments for the holders.

Negatives

• Stock options with an exercise price equal to or greater than the $23.50 offer price were cancelled without any cash payment.
• The company is no longer a publicly traded entity as it has become a wholly owned subsidiary of Zydus.

Risks

• The company has ceased to be an independent public entity, eliminating future upside potential for public shareholders.

Future Outlook

The company has been acquired and is now a wholly owned subsidiary of Zydus Worldwide DMCC; therefore, no further public guidance or forward-looking statements are applicable.

Management Comments

• The transaction was executed pursuant to the Agreement and Plan of Merger dated May 13, 2026.

Industry Context

StockSavvy.ai notes that this acquisition represents continued consolidation in the pharmaceutical sector, where larger entities are absorbing mid-cap firms to bolster product pipelines and market share.

Comparison to Industry Standards

• The all-cash tender offer structure is a standard mechanism for pharmaceutical take-privates.
• The treatment of unvested equity and in-the-money options aligns with typical change-in-control provisions found in industry merger agreements.

Legal Proceedings

• The transaction was completed pursuant to a definitive Merger Agreement.

Stakeholder Impact

• Shareholders have been cashed out at the agreed offer price.
• Employees and management are now part of the Zydus organization.

Next Steps

• Delisting of Assertio Holdings, Inc. common stock from public exchanges.

Key Dates

Keywords

Assertio Holdings, ASRT, Merger, Acquisition, Zydus, Form 4, Insider Transaction